<!-- Fragment 3  -->
<tr>
    <td>
         <table width="550" align="center" border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, HelveticaNeue, Helvetica, sans-serif; background: #005678;border-collapse:collapse;">
        <tr>
            <td width="500" style="padding:25px">
                <table align="center" border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, HelveticaNeue, Helvetica, sans-serif; background-color: #ffffff;border-collapse:collapse" bgcolor="#e8e8ea">
                    <tr>
                    	<td style="padding: 25px 15px">
                <strong style="font-size: 26px;color:#faa21b;margin-top:17px">
                    Phase 2 pivotal study design
                </strong>
                <br><br>
                <strong style="font-size:22px;font-weight: bold;color:#005678">
                    The largest prospective study in relapsed or refractory (R/R) all to date<sup>{{citationNumber[7]}}</sup>
                </strong>
                <br><br>
                <strong style="font-size: 18px;color:#005678;margin-bottom:0px">
                    Inclusion Criteria<sup>{{citationNumber[6]}}</sup>:
                </strong>
                <table style="font-family: arial; font-size: 18px;color:#005678" border="0">
                    <tr>
                        <td style="color:#faa21b; vertical-align: top">&#x25cf;</td>
                        <td colspan="2" style="line-height: 1.333;">Age &ge; 18 years</td>
                    </tr>
                    <tr>
                        <td style="color:#faa21b; vertical-align: top">&#x25cf;</td>
                        <td colspan="2">Ph-negative R/R B-precursor ALL</td>
                    </tr>
                    <tr>
                        <td></td>
                        <td style="color:#faa21b; vertical-align: top">&omicron;</td>
                        <td>Early relapse (duration of first remission &le; 12 months)</td>
                    </tr>
                    <tr>
                        <td colspan="2"></td>
                        <td><strong>OR</strong></td>
                    </tr>
                    <tr>
                        <td></td>
                        <td style="color:#faa21b; vertical-align: top">&omicron;</td>
                        <td>Any relapse or refractory disease after first salvage therapy</td>
                    </tr>
                    <tr>
                        <td colspan="2"></td>
                        <td><strong>OR</strong></td>
                    </tr>
                    <tr>
                        <td></td>
                        <td style="color:#faa21b; vertical-align: top">&omicron;</td>
                        <td>Relapse within 12 months of allogeneic HSCT</td>
                    </tr>
                    <tr>
                        <td colspan="2"></td>
                        <td><strong>AND</strong></td>
                    </tr>
                    <tr>
                        <td></td>
                        <td style="color:#faa21b; vertical-align: top">&omicron;</td>
                        <td>&ge; 10% blasts in bone marrow</td>
                    </tr>
                </table>
                <br>
                <strong style="font-size: 18px;color:#005678;margin-bottom:0px">
                    Exclusion Criteria<sup>{{citationNumber[6]}}</sup>:
                </strong>
                <table style="font-family: arial; font-size: 18px;color:#005678" border="0">
                    <tr>
                        <td style="color:#faa21b; vertical-align: top">&#x25cf;</td>
                        <td colspan="2" style="line-height: 1.333;">Late relapse patients (a CR lasting for &gt; 12 months)</td>
                    </tr>
                </table>
                <p style="font-size: 22px;padding: 30px 0;color:#005678;border-top:2px #bfbfbf solid;text-align:center ">
                    Phase 2, open-label, multicenter, single-arm&nbsp;clinical trial<sup>{{citationNumber[6]}}</sup>
                </p>
                <p style="text-align: center">
                    <img src="img-06.png" style="margin-top: -29px;margin-bottom: 20px;">
                </p>
                <strong style="font-size: 22px;color:#005678;margin:0">
                    Study Endpoints<sup>{{citationNumber[6]}}-{{citationNumber[9]}}</sup>
                </strong><br>
                        </td>
                    </tr>
                    <tr>
                    <td>
                <table style="font-size:18px;color:#005678;border-top:1px solid #000;border-bottom:1px solid #000;width:100%">
                    <tr style="background:#efefef">
                        <td colspan="2" style="padding:15px">
                            <strong>Primary</strong>
                        </td>
                    </tr>
                    <tr>
                        <td style="color:#faa21b; vertical-align: top;padding:15px 0 15px 15px">&#x25cf;</td>
                        <td style="line-height: 1.333;padding:0px">CR/CRh* within the first 2 cycles of treatment</td>
                    </tr>
                    <tr style="background:#efefef">
                        <td colspan="2" style="padding:15px">
                            <strong>Secondary</strong>
                        </td>
                    </tr>
                    <tr>
                        <td style="color:#faa21b; vertical-align: middle;padding:15px 0 0 15px">&#x25cf;</td>
                        <td style="line-height: 1.333;padding:15px 0 0 0">CR</td>
                    </tr>
                    <tr>
                        <td style="color:#faa21b; vertical-align: top;padding:0px 0 0px 15px">&#x25cf;</td>
                        <td style="line-height: 1.333;padding:0px">CRh<sup>*</sup></td>
                    </tr>
                    <tr>
                        <td style="color:#faa21b; vertical-align: top;padding:0px 0 0px 15px">&#x25cf;</td>
                        <td style="line-height: 1.333;padding:0px">Duration of response (DOR)/relapse-free survival (RFS)</td>
                    </tr>
                    <tr>
                        <td style="color:#faa21b; vertical-align: top;padding:0px 0 0px 15px">&#x25cf;</td>
                        <td style="line-height: 1.333;padding:0px">HSCT realization</td>
                    </tr>
                    <tr>
                        <td style="color:#faa21b; vertical-align: top;padding:0px 0 15px 15px">&#x25cf;</td>
                        <td style="line-height: 1.333;padding:0px 0px 15px 0">Incidence of adverse reactions</td>
                    </tr>
                    <tr style="background:#efefef">
                        <td colspan="2" style="padding:15px">
                            <strong>Exploratory</strong>
                        </td>
                    </tr>
                    <tr>
                        <td style="color:#faa21b; vertical-align: top;padding:0px 0 0px 15px">&#x25cf;</td>
                        <td style="line-height: 1.333;padding:0px">Minimal residual disease (MRD) response was defined as MRD by polymerase chain reaction (PCR) &lt; 1 x 10<sup>-4</sup></td>
                    </tr>
                    <tr>
                        <td colspan="2" style="line-height: 1.333;padding:8px 0 10px 15px;background:#efefef"><strong>Endpoint assessment </strong>was determined by bone marrow biopsies/MRD testing (every 28 days).</td>
                    </tr>
                </table>
                        </td>
                    </tr>
                    <tr>
                        <td style="padding: 25px 15px">
                <strong style="font-size: 26px;color:#faa21b">
                    Phase 2 pivotal study results
                </strong>
                            <br><br>
                <span style="font-size: 22px;font-weight: normal;color:#005678;margin:0 0 0 0">
                    <strong>Primary endpoint (CR/CRh*) achieved</strong><br>
                    <span style="font-size:18px">
                        During the first 2 treatment cycles of BLINCYTO<sup>&reg;</sup>
                    </span>
                </span>
                <p style="text-align: center">
                    <img src="img-07.png" style="margin-top: 50px;">
                </p>
                <table style="font-size:18px;color:#005678;">
                    <tr>
                        <td style="color:#faa21b; vertical-align: top;padding:0px 0 0px 0px">&#x25cf;</td>
                        <td style="line-height: 1.333;padding:0px">Probability of attaining CR/CRh<sup>*</sup> was not affected by age, history of transplant, number of prior salvage therapies, or primary refractory status<sup>{{citationNumber[7]}}</sup></td>
                    </tr>
                    <tr>
                        <td style="color:#faa21b; vertical-align: top;padding:0px 0 0px 0px">&#x25cf;</td>
                        <td style="line-height: 1.333;padding:0px">81% of responses occurred within Cycle 1 (n=62/77)<sup>{{citationNumber[6]}}</sup></td>
                    </tr>
                </table>
                            <br>
                <strong style="font-size: 26px;font-weight: bold;color:#faa21b;margin-bottom:0px">
                    Secondary and exploratory endpoints achieved
                </strong>
                <p style="text-align: center;margin-top: -10px">
                    <img src="img-08.png" style="margin-top: 0px;">
                </p>
                <span style="text-align: center;display:block;padding:0 15px 0 0;font-size: 18px;color:#005678">
                    With CR/CRh<sup>*</sup> also had an <strong>MRD response</strong> (defined as MRD by PCR &lt; 1 x 10<sup>-4</sup>)<sup>{{citationNumber[6]}}</sup>
                </span>
                            <br><br>
                <span style="font-size: 18px;color:#005678">
                    <strong>MRD Response and Survival Rates</strong><br />
                    Patients who converted to a MRD-negative status within 2 cycles of BLINCYTO<sup>&reg;</sup> experienced a longer overall survival compared with those who remained MRD positive.<sup>{{citationNumber[12]}}</sup>
                </span>
                <p style="text-align: center">
                    <img src="img-09.png" style="margin-top: 0px;">
                </p>
                <span style="display:block;text-align: center;padding:0 15px 0 0;font-size: 18px;color:#005678">
                    of patients who achieved CR/CRh<sup>*</sup> went on to receive allogeneic transplant<sup>{{citationNumber[6]}}</sup>
                </span>
                <p style="text-align: center">
                    <img src="img-10.png" style="margin-top: 0px;">
                </p>
                <span style="font-size: 16px;font-weight: normal;color:#005678;">
                    CR = complete response; CR was defined as &le; 5% of blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts (platelets &gt; 100,000/microliter and absolute neutrophil counts [ANC] &gt; 1,000/microliter).<sup>{{citationNumber[6]}}</sup><br />
                    CRh<sup>*</sup> = complete response with partial hematological recovery; CRh<sup>*</sup> was defined as &le; 5% of blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets &gt; 50,000 /microliter and ANC > 500/microliter).<sup>{{citationNumber[6]}}</sup>
                </span>
                    	</td>
                    </tr>
                     <tr>
                     	<td style="text-align: center;background:#ffffff;padding: 0 30px auto; color:#fff;font-weight: bold;font-size: 22px;padding-bottom:30px">
                         	<table  cellspacing="0" cellpadding="0" bgcolor="#ffffff" align="center" style="margin:0px auto 0;border-collapse:collapse" >
                                <tr><td align="center" style="font-family: arial; padding:15px 15px;padding-bottom:15px;background: #faa21b"> <a href="#" target="_blank" style="font-size:22px;color:#ffffff;text-decoration:none;vertical-align:middle;"><strong>Learn more about <span style="white-space:nowrap">BLINCYTO<sup>&reg;</sup> efficacy &gt;</span></strong></a></td></tr>
                    </table>
                        </td>
                     </tr>
                </table>

            </td>
        </tr>
        </table>
    </td>
</tr>